Kristen Sheppard

Kristen Sheppard joined Centessa in June 2022 as Senior Vice President, Investor Relations and Corporate Communications. Ms. Sheppard has more than 25 years of experience in building and leading successful investor relations, corporate communications and public affairs functions across the biotechnology, medical device and technology sectors.

Ms. Sheppard joined Centessa from Dicerna Pharmaceuticals, Inc. where she served as Senior Vice President, Investor Relations and Corporate Communications through its acquisition by Novo Nordisk. Prior to Dicerna, Ms. Sheppard was Senior Vice President, Investor Relations and Corporate Communications at Akebia Therapeutics, Inc. Ms. Sheppard was also Vice President, Investor Relations and Counsel at NxStage Medical, Inc. from 2008 through its acquisition by Fresenius Medical Care in 2019, serving most recently as the company’s Associate General Counsel. Prior to NxStage, Ms. Sheppard held senior leadership roles in investor relations for publicly traded and pre-IPO companies within the technology sector, and also served as senior government affairs and public policy counsel to various healthcare entities.

Ms. Sheppard holds a Juris Doctor from Suffolk University Law School and a Bachelor of Arts in political science from the University of New Hampshire. She is a member of the New Hampshire Bar Association.